Company intelligence / Profile preview

Merlin Nexus II

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Merlin Nexus II is a later-stage venture capital fund dedicated to the life sciences and healthcare industries. Co-managed by Merlin BioMed Group and Nexus Life Science Partners, the fund specializes in crossover investments, targeting both private and public companies in sectors such as biotechnology, pharmaceuticals, and medical devices. The fund's strategy focuses on identifying late-stage opportunities with clear paths to liquidity, typically within a two-to-three-year horizon. Key investments from this fund have included companies like Micromet, Sunesis Pharmaceuticals, and Cougar Biotechnology.

Industry: Investors

Partnerships

Nexus Life Science Partners

Beyond the preview

Go deeper on Merlin Nexus II.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merlin Nexus II.

Explore the full profile